Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients

被引：0
|
作者：
Lin Hu
Qi Huang
Shiqiong Huang
Zeying Feng
机构：
[1] the First Hospital of Changsha,Department of Pharmacy
[2] Xiangya Hospital,Department of Pharmacy
[3] Central South University,Clinical Trial Institution Office
[4] Liuzhou Hospital of Guangzhou Women and Children’s Medical Center,Center of Clinical Pharmacology
[5] the Third Xiangya Hospital,undefined
[6] Central South University,undefined
来源：
European Journal of Clinical Pharmacology | 2023年 / 79卷
关键词：
Voriconazole; Therapeutic drug monitoring; CYP2C19 phenotype; Paediatric patients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1271 / 1278
页数：7
相关论文
共 50 条
  • [31] CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation
    Takahashi, Takuto
    Mohamud, Maryam A.
    Smith, Angela R.
    Jacobson, Pamala A.
    Jaber, Mutaz M.
    Alharbi, Abeer F.
    Fisher, James
    Kirstein, Mark N.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (09)
  • [32] Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes
    Hicks, J. Kevin
    Crews, Kristine R.
    Flynn, Patricia
    Haidar, Cyrine E.
    Daniels, Calvin C.
    Yang, Wenjian
    Panetta, John C.
    Pei, Deqing
    Scott, Jeffrey R.
    Molinelli, Alejandro R.
    Broeckel, Ulrich
    Bhojwani, Deepa
    Evans, William E.
    Relling, Mary V.
    PHARMACOGENOMICS, 2014, 15 (08) : 1065 - 1078
  • [33] Development of a CYP2C19 Genotype Guided Dosing Algorithm for Voriconazole
    Mangal, Naveen
    Hamadeh, Issam
    Samant, Tanay
    Schmidt, Stephan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S53 - S53
  • [34] Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
    Hui-Yan Shi
    Jin Yan
    Wen-Hui Zhu
    Guo-Ping Yang
    Zhi-Rong Tan
    Wei-Hua Wu
    Gan Zhou
    Xiao-Ping Chen
    Dong-Sheng Ouyang
    European Journal of Clinical Pharmacology, 2010, 66 : 1131 - 1136
  • [35] Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
    Shi, Hui-Yan
    Yan, Jin
    Zhu, Wen-Hui
    Yang, Guo-Ping
    Tan, Zhi-Rong
    Wu, Wei-Hua
    Zhou, Gan
    Chen, Xiao-Ping
    Ouyang, Dong-Sheng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (11) : 1131 - 1136
  • [36] Clinical importance of the CYP2C19*17 variant allele for voriconazole
    Dolton, Michael J.
    McLachlan, Andrew J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (01) : 137 - 138
  • [37] Therapeutic Drug Monotoring: CYP2C19 genetic polymorphism and major depression
    Adamovic, I
    Michaelis, S.
    Streit, F.
    Binder, L.
    Degner, D.
    PHARMACOPSYCHIATRY, 2020, 53 (02) : 98 - 98
  • [38] Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype
    Helsby, Nuala A.
    Lo, Wing-Yee
    Simpson, Ian J.
    Voss, David M.
    Logan, Kaye E.
    Searle, Martin
    Schollum, John B. W.
    de Zoysa, Janak R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (05) : 516 - 519
  • [39] A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis
    Kim, Yun
    Rhee, Su-jin
    Park, Wan Beom
    Yu, Kyung-Sang
    Jang, In-Jin
    Lee, And Seunghwan
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (02):
  • [40] The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19☆35 and CYP2C19☆2 Alleles
    Chaudhry, Amarjit S.
    Prasad, Bhagwat
    Shirasaka, Yoshiyuki
    Fohner, Alison
    Finkelstein, David
    Fan, Yiping
    Wang, Shuoguo
    Wu, Gang
    Aklillu, Eleni
    Sim, Sarah C.
    Thummel, Kenneth E.
    Schuetz, Erin G.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1226 - 1235
12345